U.S. Markets open in 4 hrs 44 mins

Landos Biopharma, Inc. (LABP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.15+0.22 (+2.22%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.93
Open9.88
Bid0.00 x 2200
Ask0.00 x 1100
Day's Range9.75 - 10.24
52 Week Range9.10 - 16.99
Volume117,180
Avg. Volume383,935
Market Cap398.368M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
    Benzinga

    Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation

    The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patient dosing in the first half of 2022. The 36-subject Phase 1b study is designed to evaluate the safety and pharmacokinetics of omilancor. Patients will be randomized in a 1:1:1 ratio to receive either omilancor 500 mg twice daily, omilancor 1000 mg once daily, or placebo for 12 weeks. Each of the treatment arms will include 12 subjects. The primary safety endpoint will measure the frequency and severity of adverse events and changes in clinical chemistry and hematology from baseline. The secondary endpoint is a pharmacokinetic analysis of omilancor plasma levels at various time intervals post-dosing, in addition to evaluating the mean concentration of omilancor in esophageal biopsy tissue after 12 weeks of dosing. Omilancor is an orally active, gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-like 2 pathway impacting the gastrointestinal tract. LANCL2 plays a vital role in the immunoregulatory process. The Company reported initial Phase 2 results of omilancor evaluating patients with ulcerative colitis in 2021 and expects to initiate a Phase 3 trial in the second half of 2021. Additionally, Landos plans to initiate a Phase 2 trial of omilancor in patients with Crohn's disease in the first half of this year. Price Action: LABP shares are trading 6.4% higher at $9.85 on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaIonis Antisense Oligonucleotides To Be Evaluated With Progenity's Drug Delivery SystemAzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Barrons.com

    Bausch Health and Landos Biopharma See Activist Action

    Icahn Capital reached a pact to appoint Bausch Health directors. Perceptive Advisors disclosed a large stake in Landos Biopharma.

  • Barrons.com

    The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market

    A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well. Vor Biopharma stock rocketed at its open.